Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lispro Mix 75/25 vs Glargine in Type 2 Diabetes
NCT00551538Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2003
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin lispro in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Combined morning and evening mean 2 hour postprandial plasma glucose at 12 weeks. Started May 2003; status: completed.
02
Drugs
insulin lispro
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00551538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00551538.